The human monoclonal antibody ustekinumab blocks the biologic activity of IL-12 and IL-23 by inhibiting receptors of these two cytokines on T cells, natural killer cells, and antigen-presenting cells.

is developing an orally administered small molecule—apilimod (STA-5326)—targeting IL-12/23 for rheumatoid arthritis. Unlike Stelara and ABT-874, which inhibit IL-12/23 by binding to and ...

A surge of generics, biosimilars, and innovative therapies is expected in 2025, addressing conditions from cancer to chronic ...

Teva Pharmaceuticals and Alvotech have announced the US launch of the Selarsdi (ustekinumab-aekn) injection, a biosimilar to Johnson & Johnson’s Stelara (ustekinumab). The product is indicated ...

This Monday, Bio-Thera Solutions and Dr. Reddy’s Laboratories SA announced that they had entered into commercialization and licensing agreements for proposed ustekinumab and golimumab ...

JERSEY CITY, N.J., March 27, 2025 /PRNewswire/ -- Celltrion, Inc., today announced that STEQEYMA ® (ustekinumab-stba), a biosimilar to STELARA ® (ustekinumab) has been added to the Costco Member ...

--(BUSINESS WIRE)--Fresenius Kabi, an operating company of Fresenius, and Formycon AG, a leading, independent developer of high-quality biosimilars, announced today that the ustekinumab biosimilar ...

The European Commission (EC) has approved ustekinumab for the treatment of moderately to severely active Crohn’s disease in paediatric patients weighing at least 40 kg. The decision follows evidence ...